16 September 2026 editorial review · Trial
ELSA: EarLy Surveillance for Autoimmune diabetes (UK): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Primary-agent trial review — 16 September 2026
Assessment: Official program says screening paused and ages2–17; corrected active-open3–13 presentation while distinguishing original cohort age bands. Historical observational screening outcomes are not new results from this refresh.
Sources for this record: The ELSA Study: current screening pause and age range (community); ELSA screening study ISRCTN97974414 (registry); Presentation and characteristics of children with screen-detected type 1 diabetes: learnings from the ELSA general population pediatric screening study (peer-reviewed).
Limits: Source access and review depth vary. Registry fields establish the registered study, not clinical benefit, product approval or current local access. Cited-source reachability alone was not treated as verification of its claims.